Boston, MA -- (SBWIRE) -- 01/10/2014 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: Infosys Ltd ADR (NYSE:INFY), Immunomedics, Inc. (NASDAQ:IMMU), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Galectin Therapeutics Inc. (NASDAQ:GALT)
Infosys Ltd ADR (NYSE:INFY) increased 5.24% at the price of $59.09 recently on a traded volume of 2.51 million shares, in comparison to 907,015.00 shares of average trading volume. So far this year, the stock is up over 4.72%.
The company has a total market capitalization of $33.80 billion and its total outstanding shares are 571.40 million. Infosys Limited (Infosys) provides business consulting, technology, engineering and outsourcing services. Its end-to-end business solutions include consulting and systems integration comprising consulting, enterprise solutions.
For How Long INFY will Fight for Profitability? Read This Trend Analysis report
Immunomedics, Inc. (NASDAQ:IMMU) soared 15.06% at the trading price of $5.96 on a traded volume of 4.58 million shares till now, whereas its average trading volume is 966,730.00 shares. In the last three months, the stock is up 7.55%. The Intra-day range for the stock is $5.55 and $6.04. Immunomedics, Inc. is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
For How Long IMMU Gloss will Attract Investors? Find out via this report
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) jumped up 58.76% at the $437.96 recently. So far in three months, the stock is up 604.19%. The 52-week range for the stock is $30.38 and $484.00. Its introductory price for the day was $373.00, with the overall traded volume of 3.18 million shares. Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Will ICPT Continue To Move Higher? Find Out Here
Galectin Therapeutics Inc. (NASDAQ:GALT) after opening its shares at the price of $17.02, jumped up 11.78% , its recent trading price was $15.08 for the day. The stock moved on a traded volume of 4.01 million shares, in comparison to 382,312.00 shares of average trading volume.
The 52-week range for the stock is $1.99 and $17.88. Its introductory price for the day was $17.02. Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02
Why Should Investors Buy GALT After The Recent Gain? Just Go Here and Find OutAbout winstonsmallcap.com
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/ and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)